March 29 - follow the money, page-7

OPMD is our program Sean. Promising early pre-clinical results in OPMD will finally validate our proprietary ddrnai technology to the world and help industry analysts and the general market more reliably and realistically value our multi-target pipeline once it is articulated this quarter. This strategy of allowing Axovant to release OPMD results on the 29th March before we announce our new pipeline is a brilliant masterstroke that will send our shareprice into the stratosphere. Good luck all holders. Three days to Elysium.